Boehringer Ingelheim’s Drug Ofev Approved by FDA

The U.S. Food and Drug Administration approved Boehringer Ingelheim‘s drug Ofev (nintedanib), which has become the first treatment to be approved by the agency for a rare lung condition -- interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD.

• Ofev capsules to slow rate of decline in pulmonary function in people with SSc-ILD
• Ofev was originally approved in 2014 for adult patients with idiopathic pulmonary fibrosis (IPF), which is another interstitial lung condition
• Ofev received priority review designation and orphan drug designation
• NOTE: July 25, FDA Panel Recommends Approval of Boehringer Ingelheim’s Ofev

To view the source of ...